Case Study

Making New Drug Selections Safe - Estimating the Possibility of Failure

Too often, decisions about which products to purchase are often made or influenced by:

- Purchasing groups
- Marketing
- Cost
- Availability

Evaluation and input from those using the product would decrease potential for error in the future!

Reference: ISMP Medication Safety Alert!

Objective:

Apply FMEA principles to a common drug distribution issue.

Case Study Worksheet

| Steps in the Process | Failure Mode | Failure Causes | Failure Effects | Likelihood of Occurrences (1-5) | Likelihood of detection (1-5) | Severity (1-5) | Risk Profile Number (RPN) | Actions to Reduce |
|----------------------------|-----------------|-------------------|--------------------|---------------------------------------|-------------------------------------|-------------------|------------------------------------|----------------------|
| 1 | | | | | | | | |
| 2 | | | | | | | | |
| 3 | | | | | | | | |
| | | | | | | | TOTAL RPN (Sum of all RPNs): | |

New Contract begins Jan 1, 2004

- New Product arrives
- Access potential for error

Hydrocortisone



Methylprednisolone



Betamethasone



Furosemide



Apply FMEA

- Talk about steps you would take
- Identify potential failures

| Steps in the Process | Failure Mode | Failure Causes | Failure Effects | Likelihood of Occurrences (1-10) | Likelihood of detection (1-10) | Severity (1-10) | Risk Profile Number | Actions to Reduce |
|----------------------------|-----------------|-------------------|--------------------|--|--------------------------------------|--------------------|---------------------------|-------------------------|
| 1 | | | | | | | | |
| 2 | | | | | | | | |

Debrief

What could go wrong?

Apply Risk Priority Number

Multiply the three scores obtained for likelihood of occurrences, likelihood of detection, and severity

Identify Highest RPNs

Plan improvement efforts

Share Ideas